Advertisement
UK markets close in 8 hours 8 minutes
  • FTSE 100

    7,947.94
    +15.96 (+0.20%)
     
  • FTSE 250

    19,820.78
    +10.12 (+0.05%)
     
  • AIM

    743.13
    +1.02 (+0.14%)
     
  • GBP/EUR

    1.1681
    +0.0012 (+0.11%)
     
  • GBP/USD

    1.2608
    -0.0030 (-0.24%)
     
  • Bitcoin GBP

    55,882.86
    +412.34 (+0.74%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.76
    +0.41 (+0.50%)
     
  • GOLD FUTURES

    2,213.10
    +0.40 (+0.02%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,558.25
    +165.41 (+1.01%)
     
  • DAX

    18,479.64
    +2.55 (+0.01%)
     
  • CAC 40

    8,230.21
    +25.40 (+0.31%)
     

Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017

Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017

Novartis: What Are the Major Growth Drivers for 2018? In 4Q17, Novartis’s (NVS) Cosentyx reported global sales of $615.0 million, which is a year-over-year (or YoY) increase of 53.0% on a constant currency basis and 11.0% growth quarter-over-quarter. This growth was driven by the drug’s rapid uptake in all approved indications and in all geographies, with a focus on the US and Europe.